Login to Your Account

NewCo News

Strategic Buys Fuel MAb Developer Immune Pharma

By Marie Powers
Staff Writer

Friday, December 28, 2012
In less than three years, privately held Immune Pharmaceuticals has matured from a start-up launched with a single monoclonal antibody (MAb) licensed from Canada's iCo Therapeutics Inc. into a biotech capable of absorbing the assets of publicly traded EpiCept Corp. in an all-stock deal.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription